Research programme: amyloid precursor protein secretase inhibitors - Elan

Drug Profile

Research programme: amyloid precursor protein secretase inhibitors - Elan

Alternative Names: ELND007

Latest Information Update: 08 Aug 2011

Price : $50

At a glance

  • Originator Elan Pharmaceuticals
  • Class Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Alzheimer's disease

Most Recent Events

  • 03 Aug 2011 Early investigations for β-secretase inhibitors are ongoing; preclinical development for ELND 007 has been discontinued
  • 13 Apr 2007 Preclinical development is ongoing
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top